DelveInsight's Primary Progressive Multiple Sclerosis (PPMS) - Epidemiology Forecast 2034 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Primary Progressive Multiple Sclerosis (PPMS) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Primary Progressive Multiple Sclerosis Epidemiology Forecast

<h2>Key Highlights</h2>
<ul>
<li>Primary Progressive Multiple Sclerosis (PPMS), is a distinct form of Multiple Sclerosis, which is characterized by a gradual worsening of neurological function from the onset, without the typical relapses and remissions seen in other forms of multiple sclerosis.</li>
<li>The progressive phase of multiple sclerosis (primary progressive and secondary progressive) is the result of long-lasting degenerative changes, which appear only when an age threshold is reached and progresses at similar rates.</li>
<li>PPMS is the least common type of disease, diagnosed in about 10&ndash;15% of MS patients.</li>
<li>As per Delveinsight, the total number of diagnosed prevalent cases of Primary Progressive Multiple Sclerosis in the US is ~120,000 in 2023.</li>
<li>Women are more likely to develop PPMS than men. In the United States, the number of women cases of Primary Progressive Multiple Sclerosis are about 3 times more than the cases of men.</li>
<li>Primary Progressive Multiple Sclerosis is more common in the age group of 45-54 years and approximate 40,000 cases were related to this age group in US during year 2023.</li>
</ul>
DelveInsight&rsquo;s&nbsp; &ldquo;Primary Progressive Multiple Sclerosis (PPMS) &ndash; Epidemiology Forecast &ndash; 2034&rdquo; report delivers an in-depth understanding of Primary Progressive Multiple Sclerosis, historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
The table given below further depicts the key segments provided in the report:
<table class="MsoTableGrid" style="border: none; width: 66.7195%;" border="1" cellspacing="0" cellpadding="0">
<tbody>
<tr>
<td style="width: 31.3997%; border-width: 1pt; border-color: windowtext; border-image: initial; padding: 0cm 5.4pt; background-color: #eff4ff;" valign="top" width="158"> 
Study Period
 </td>
<td style="width: 68.6003%; border-top-width: 1pt; border-right-width: 1pt; border-bottom-width: 1pt; border-top-color: windowtext; border-right-color: windowtext; border-bottom-color: windowtext; border-image: initial; border-left: none; padding: 0cm 5.4pt; background-color: #eff4ff;" valign="top" width="443">
2021-2034
</td>
</tr>
<tr>
<td style="width: 31.3997%; border-right-width: 1pt; border-bottom-width: 1pt; border-left-width: 1pt; border-right-color: windowtext; border-bottom-color: windowtext; border-left-color: windowtext; border-image: initial; border-top: none; padding: 0cm 5.4pt;" valign="top" width="158"> 
Forecast Period
 </td>
<td style="width: 68.6003%; border-top: none; border-left: none; border-bottom-width: 1pt; border-bottom-color: windowtext; border-right-width: 1pt; border-right-color: windowtext; padding: 0cm 5.4pt;" valign="top" width="443">
2024&ndash;2034
</td>
</tr>
<tr>
<td style="width: 31.3997%; border-right-width: 1pt; border-bottom-width: 1pt; border-left-width: 1pt; border-right-color: windowtext; border-bottom-color: windowtext; border-left-color: windowtext; border-image: initial; border-top: none; padding: 0cm 5.4pt; background-color: #eff4ff;" valign="top" width="158"> 
Geographies Covered
 </td>
<td style="width: 68.6003%; border-top: none; border-left: none; border-bottom-width: 1pt; border-bottom-color: windowtext; border-right-width: 1pt; border-right-color: windowtext; padding: 0cm 5.4pt; background-color: #eff4ff;" valign="top" width="443">
US, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan
</td>
</tr>
<tr>
<td style="width: 31.3997%; border-right-width: 1pt; border-bottom-width: 1pt; border-left-width: 1pt; border-right-color: windowtext; border-bottom-color: windowtext; border-left-color: windowtext; border-image: initial; border-top: none; padding: 0cm 5.4pt;" valign="top" width="158"> 
Epidemiology
 </td>
<td style="width: 68.6003%; border-top: none; border-left: none; border-bottom-width: 1pt; border-bottom-color: windowtext; border-right-width: 1pt; border-right-color: windowtext; padding: 0cm 5.4pt;" valign="top" width="443">
Segmented by:
<ul>
<li>Diagnosed Prevalent Cases</li>
<li>Region-Specific Cases</li>
<li>Gender-Specific Cases</li>
<li>Age-Specific Cases</li>
<li>Total Treated Cases</li>
</ul>
</td>
</tr>
</tbody>
</table>
<h2>Primary Progressive Multiple Sclerosis (PPMS): Disease Understanding&nbsp;</h2>
<h3>Primary Progressive Multiple Sclerosis (PPMS) Overview, and Diagnosis</h3>
Primary Progressive Multiple Sclerosis (PPMS) is a rare and challenging form of multiple sclerosis, accounting for about 10&ndash;15% of MS cases. Unlike relapsing forms, PPMS is characterized by a gradual, continuous decline in neurological function without periods of remission or relapses. Over time, individuals with PPMS experience accumulating disability, particularly affecting mobility. The disease progression is steady, leading to long-term impairment, making early diagnosis and effective management crucial for improving the patient's quality of life.
Diagnosing PPMS requires meeting specific criteria due to its unique progression pattern. The process includes a careful medical history, neurological exam, and tests like MRI, spinal fluid analysis, and blood tests to rule out other conditions. The primary diagnostic criteria are one year of continuous disease progression and the presence of two out of three key markers: typical brain lesions, multiple spinal cord lesions, or signs of immune activity in the spinal fluid (e.g., oligoclonal bands). Since PPMS progresses gradually, it can take 2&ndash;3 years longer to diagnose compared to other MS types, further complicating early intervention and treatment.
Although there is no cure for PPMS, various treatment approaches focus on managing symptoms and slowing disease progression. These include Disease-Modifying Therapies (DMTs) such as OCREVUS (ocrelizumab) and OCREVUS ZUNOVO (ocrelizumab and hyaluronidase-ocsq), as well as symptomatic management and lifestyle adjustments. Symptomatic management remains a cornerstone of care.
<h3>Primary Progressive Multiple Sclerosis (PPMS) Epidemiology</h3>
The Primary Progressive Multiple Sclerosis (PPMS) epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Cases Of Primary Progressive Multiple Sclerosis, Gender Specific Cases of Primary Progressive Multiple Sclerosis, Age Specific Cases of Primary Progressive Multiple Sclerosis, and Total Treated Cases Of Primary Progressive Multiple Sclerosis in the United States, EU4 countries (Germany, France, Italy, Spain) and the United Kingdom, and Japan from 2021 to 2034.
<ul>
<li>In the 7MM, the total number of diagnosed prevalent cases of Primary Progressive Multiple Sclerosis (PPMS) were ~200,000 in 2023.</li>
<li>The US accounts for the highest prevalent cases of PPMS, and about 60% of the total cases were from US in year 2023.</li>
<li>In 2023, the prevalent cases of PPMS in Male in the United States were ~30,000 in 2023 and it is expected to increase by CAGR of 3%.</li>
<li>Germany has the most prevalent cases of Primary Progressive Multiple Sclerosis among EU4 and UK, whereas the Spain has the fewest.</li>
<li>The total diagnosed prevalent cases of Primary Progressive Multiple Sclerosis in Japan was expected to reach ~1100 by 2034.</li>
</ul>
<h2>Scope of the Report</h2>
<ul>
<li>The report covers a segment of key events, an executive summary, and a descriptive overview of Primary Progressive Multiple Sclerosis (PPMS), explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.</li>
<li>Comprehensive insight into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, and disease progression have been provided.</li>
<li>A detailed review of current challenges in establishing diagnosis and diagnosis rate is provided.</li>
</ul>
<h2>Primary Progressive Multiple Sclerosis (PPMS) Report Insights</h2>
<ul>
<li>Patient Population</li>
<li>Country-wise Epidemiology Distribution</li>
</ul>
<h2>Primary Progressive Multiple Sclerosis (PPMS) Report Key Strengths</h2>
<ul>
<li>Eleven-year Forecast</li>
<li>The 7MM Coverage&nbsp;</li>
<li>Primary Progressive Multiple Sclerosis (PPMS) Epidemiology Segmentation</li>
</ul>
<h2>Primary Progressive Multiple Sclerosis (PPMS) Report Assessment</h2>
<ul>
<li>Epidemiology Segmentation</li>
<li>Current Diagnostic Practices</li>
</ul>
<h2>FAQs</h2>
<h3>Epidemiology Insights</h3>
<ul>
<li>What are the disease risks, burdens, and unmet needs of Primary Progressive Multiple Sclerosis? What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Primary Progressive Multiple Sclerosis?</li>
<li>What is the historical and forecasted Primary Progressive Multiple Sclerosis patient pool in the United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan?</li>
<li>What is the diagnostic pattern of Primary Progressive Multiple Sclerosis?</li>
<li>Which clinical factors will affect Primary Progressive Multiple Sclerosis?</li>
<li>Which factors will affect the increase in the diagnosis of Primary Progressive Multiple Sclerosis?</li>
<li>Which age group has a high patient share in the Primary Progressive Multiple Sclerosis?</li>
</ul>
<h2>Reasons to buy</h2>
<ul>
<li>Insights on disease burden, details regarding diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.</li>
<li>To understand the change in Primary Progressive Multiple Sclerosis cases in varying geographies over the coming years.</li>
<li>A detailed overview of total diagnosed prevalent cases of Primary Progressive Multiple Sclerosis, gender specific cases of Primary Progressive Multiple Sclerosis, age specific cases of Primary Progressive Multiple Sclerosis, and total treated cases of Primary Progressive Multiple Sclerosis is included.</li>
<li>To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis and insights on the treatment-eligible patient pool.</li>
<li>Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.</li>
</ul>

1. Key Insights
2. Report Introduction
3. Executive Summary of PPMS
4. PPMS Epidemiology Overview at a Glance
4.1. Patient share (%) Distribution in 2021
4.2. Patient share (%) Distribution in 2034
5. Epidemiology Methodology
6. Disease Background and Overview
6.1. Introduction
6.1.1. Multiple Sclerosis
6.1.2. PPMS
6.2. Signs and Symptoms of PPMS
6.3. Pathophysiology of PPMS
6.4. Risk Factors
6.5. Diagnosis and Differential Diagnosis of PPMS
6.5.1. Magnetic resonance imaging (MRI)
6.5.2. Cerebrospinal Fluid Analysis
6.6. Diagnostic Guidelines
7. Epidemiology and Patient Population
7.1. Key Findings
7.2. Assumptions and Rationale
7.3. Total Diagnosed Prevalent Cases of PPMS in the 7MM
7.4. Total Treated Cases of PPMS in the 7MM
7.5. The United States
7.5.1. Total Diagnosed Prevalent Cases of PPMS in the United States
7.5.2. Gender-specific Cases of PPMS in the United States
7.5.3. Age-specific Cases of PPMS in the United States
7.5.4. Total Treated Cases of PPMS in the United States
7.6. EU4 and the UK
7.6.1. Total Diagnosed Prevalent Cases of PPMS in EU4 and the UK
7.6.2. Gender-specific Cases of PPMS in EU4 and the UK
7.6.3. Age-specific Cases of PPMS in EU4 and the UK
7.6.4. Total Treated Cases of PPMS in EU4 and the UK
7.7. Japan
7.7.1. Total Diagnosed Prevalent Cases of PPMS in Japan
7.7.2. Gender-specific Cases of PPMS in Japan
7.7.3. Age-specific Cases of PPMS in Japan
7.7.4. Total Treated Cases of PPMS in Japan
8. Patient Journey
9. Appendix
9.1. Bibliography
9.2. Report Methodology
10. DelveInsight Capabilities
11. Disclaimer
12. About DelveInsight
&nbsp;

DelveInsight's "Primary Progressive Multiple Sclerosis (PPMS) - Epidemiology Forecast to 2034" report delivers an in-depth understanding of the disease, historical and forecasted Primary Progressive Multiple Sclerosis (PPMS) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.